Literature DB >> 16926619

Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.

Lawrence Scahill1, Christopher J McDougle, Susan K Williams, Anastasia Dimitropoulos, Michael G Aman, James T McCracken, Elaine Tierney, L Eugene Arnold, Pegeen Cronin, Marco Grados, Jaswinder Ghuman, Kathleen Koenig, Kristen S L Lam, James McGough, David J Posey, Louise Ritz, Naomi B Swiezy, Benedetto Vitiello.   

Abstract

OBJECTIVE: To examine the psychometric properties of the Children's Yale-Brown Obsessive Compulsive Scales (CYBOCS) modified for pervasive developmental disorders (PDDs).
METHOD: Raters from five Research Units on Pediatric Psychopharmacology (RUPP) Autism Network were trained to reliability. The modified scale (CYBOCS-PDD), which contains only the five Compulsion severity items (range 0-20), was administered to 172 medication-free children (mean 8.2 +/- 2.6 years) with PDD (autistic disorder, n = 152; Asperger's disorder, n = 6; PDD not otherwise specified, n = 14) participating in RUPP clinical trials. Reliability was assessed by intraclass correlation coefficient (ICC) and internal consistency by Cronbach's alpha coefficient. Correlations with ratings of repetitive behavior and disruptive behavior were examined for validity.
RESULTS: Eleven raters showed excellent reliability (ICC = 0.97). The mean CYBOCS score was 14.4 (+/- 3.86) with excellent internal consistency (alpha = .85). Correlations with other measures of repetitive behavior ranged from r = 0.11 to r = 0.28 and were similar to correlations with measures of irritability (r = 0.24) and hyperactivity (r = 0.25). Children with higher scores on the CYBOCS-PDD had higher levels of maladaptive behaviors and lower adaptive functioning.
CONCLUSIONS: The five-item CYBOCS-PDD is reliable, distinct from other measures of repetitive behavior, and sensitive to change.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926619     DOI: 10.1097/01.chi.0000220854.79144.e7

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  58 in total

1.  Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias.

Authors:  Melisa Carrasco; Fred R Volkmar; Michael H Bloch
Journal:  Pediatrics       Date:  2012-04-23       Impact factor: 7.124

2.  Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges.

Authors:  Luigi Mazzone; Liliana Ruta; Laura Reale
Journal:  Ann Gen Psychiatry       Date:  2012-06-25       Impact factor: 3.455

3.  fMRI tracks reductions in repetitive behaviors in autism: two case studies.

Authors:  Gabriel S Dichter; Linmarie Sikich; Steve Mahorney; Jennifer N Felder; Kristen S L Lam; Lauren Turner-Brown; James Bodfish
Journal:  Neurocase       Date:  2010-02-22       Impact factor: 0.881

Review 4.  Anxiety Disorders and Obsessive-Compulsive Disorder in Individuals with Autism Spectrum Disorder.

Authors:  Valentina Postorino; Connor M Kerns; Giacomo Vivanti; Jessica Bradshaw; Martina Siracusano; Luigi Mazzone
Journal:  Curr Psychiatry Rep       Date:  2017-10-30       Impact factor: 5.285

5.  Case report: 16-Year-old male with autistic disorder with preoccupation with female feet.

Authors:  Maureen C Early; Craig A Erickson; Logan K Wink; Christopher J McDougle; Eric L Scott
Journal:  J Autism Dev Disord       Date:  2012-06

6.  Developmental disabilities modification of the Children's Global Assessment Scale.

Authors:  Ann Wagner; Luc Lecavalier; L Eugene Arnold; Michael G Aman; Lawrence Scahill; Kimberly A Stigler; Cynthia R Johnson; Christopher J McDougle; Benedetto Vitiello
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

7.  A genome scan for loci shared by autism spectrum disorder and language impairment.

Authors:  Christopher W Bartlett; Liping Hou; Judy F Flax; Abby Hare; Soo Yeon Cheong; Zena Fermano; Barbie Zimmerman-Bier; Charles Cartwright; Marco A Azaro; Steven Buyske; Linda M Brzustowicz
Journal:  Am J Psychiatry       Date:  2014-01       Impact factor: 18.112

8.  Outcome measures for clinical trials in fragile X syndrome.

Authors:  Elizabeth Berry-Kravis; David Hessl; Leonard Abbeduto; Allan L Reiss; Andrea Beckel-Mitchener; Tiina K Urv
Journal:  J Dev Behav Pediatr       Date:  2013-09       Impact factor: 2.225

9.  A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures.

Authors:  Laura C Politte; Lawrence Scahill; Janet Figueroa; James T McCracken; Bryan King; Christopher J McDougle
Journal:  Neuropsychopharmacology       Date:  2018-02-27       Impact factor: 7.853

10.  Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.

Authors:  Kimberly A Stigler; Jonathan T Diener; Arlene E Kohn; Lang Li; Craig A Erickson; David J Posey; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.